Cervical Esophageal Cancer Treatment: HeadandNeckCancerGuide.org

Cervical Esophageal Cancer

« »

Deciding on a Treatment Plan

Before starting treatment, your doctor will make sure that the following steps are completed.

Pretreatment evaluation

A full history and physical examination
An evaluation by the members of a head and neck cancer team

An upper GI endoscopy and biopsy to confirm a diagnosis of cancer
Imaging of the primary tumor, neck, chest, and abdomen
Possibly pelvic imaging, as needed
PET-CT scan if no evidence of metastatic disease
Endoscopic ultrasound if no evidence of metastatic disease

Perform lab tests
Removal of abnormal lesions found in the digestive tract to confirm an accurate staging of early stage cancer
Biopsy of metastatic disease if needed
Genetic testing if metastatic adenocarcinoma is suspected
Classification of the type of adenocarcinoma tumor (if suspected) to determine extent of surgery

Bronchoscopy as needed
Nutritional assessment and counseling
Smoking cessation advice, counseling as needed
Screen family history for genetic risks
Pretreatment medical clearance and evaluation of medical conditions

Then your doctor will recommend a course of treatment for you, depending on a number of factors. Like with all cancers in the head and neck, there are three general options to consider:

Surgical removal (with or without reconstruction)
Radiation (a few different types)
Medications (chemotherapy and biologic medications)

You should have an extensive discussion with your cancer team to decide upon the best treatment course for you personally. The options that your doctor will recommend will likely depend on the stage of cancer you have.

Squamous Cell Carcinoma and Adenocarcinoma

If you are M0 and healthy enough to undergo surgery	pTis: Endoscopic therapies, such as endoscopic resection (ER), ablation, ER followed by ablation, are preferred. Another option is surgical removal of the esophagus (esophagectomy) pT1a: ER or ER followed by ablation are preferred, or esophagectomy Superficial pT1b (Only Adenocarcinoma): ER followed by ablation or esophagectomy pT1b, N0: Esophagectomy cT1b, N+ and cT2-T4a, Any N: Chemotherapy with radiation followed by esophagectomy (or observation if no evidence of disease). For patients with adenocarcinoma, this is the preferred primary treatment. Or, Definitive chemoradiation for patients who decline surgery (recommended for cervical esophagus) or Esophagectomy alone for non-cervical esophagus tumors (for low risk lesions that are <2cm and well differentiated) If Adenocarcinoma, chemotherapy alone before, during, or after esophagectomy, is also recommended. cT4b: Definitive chemoradiation and esophagectomy only if there is evidence of leftover cancer. If squamous cell carcinoma, your physician may consider chemotherapy alone if the tumor has spread to the trachea, great vessels, or heart.
If you are M0 and not a good candidate for surgery, or You choose not to undergo surgery	pTis: Endoscopic Resection (ER) or ablation or ER followed by ablation pT1a: ER or ER followed by ablation pT1b that is not very deep: ER or ER followed by ablation or chemotherapy with radiation for bad tumors cT1b, N+ and cT2-T4a, Any N or cT4b (unresectable): For all other tumors, the options are definitive chemoradiation or palliative radiation or best supportive care.
If you are not a good candidate for surgery, and You are not a good candidate for chemotherapy or chemotherapy with radiation therapy	Your physician will consider radiation therapy to help with symptoms or will offer you a variety of interventions to give you a good quality of life. This is called “best supportive care.”
Stage IV (M1, metastatic disease)	The option here is systemic therapy and/or best supportive care. For esophageal cancer, this might include radiation, chemotherapy, drugs, and surgical procedures to remove obstruction in the esophagus.

References

¹ Krause CJ, Carey TE, Ott RW, Hurbis C, McClatchey KD, Regezi JA. Human squamous cell carcinoma. Establishment and characterization of new permanent cell lines. Arch Otolaryngol. Nov 1981;107(11):703-710.

² Moore C. Smoking and cancer of the mouth, pharynx, and larynx. JAMA: the journal of the American Medical Association. Jan 25 1965;191(4):283-286.

³ Pelucchi C, Gallus S, Garavello W, Bosetti C, La Vecchia C. Cancer risk associated with alcohol and tobacco use: focus on upper aero-digestive tract and liver. Alcohol research & health: the journal of the National Institute on Alcohol Abuse and Alcoholism. 2006;29(3):193-198.

⁴ Little MP. Cancer after exposure to radiation in the course of treatment for benign and malignant disease. The lancet oncology. Apr 2001;2(4):212-220.

⁵ Modlin IM, Shapiro MD, Kidd M. An analysis of rare carcinoid tumors: clarifying these clinical conundrums. World J Surg. 2005 Jan;29(1):92-101.

⁶ Vinik, A. I., Thompson, N., Eckhauser, F., & Moattari, A. R. (1989). Clinical features of carcinoid syndrome and the use of somatostatin analogue in its management. Acta Oncologica, 28(3), 389-402.

⁷ Mariette C, Balon J-M, Piessen G, Fabre S, Van Seuningen I, Triboulet J-P. Pattern of recurrence following complete resection of esophageal carcinoma and factors predictive of recurrent disease. Cancer. 2003;97:1616-1623.

⁸ Key C and Meisner ALW. Chapter 3: Cancer of the Esophagus, Stomach, and Small Intestine. Ries LAG, Young JL, Keel GE, Eisner MP, Lin YD, Horner M-J (editors). SEER Survival Monograph: Cancer Survival Among Adults: U.S. SEER Program, 1988-2001, Patient and Tumor Characteristics. National Cancer Institute, SEER Program, NIH Pub. No. 07-6215, Bethesda, MD, 2007.

⁹ Leggett CL, Lewis JT, Wu TT, et al. Clinical and histologic determinants of mortality for patients with Barrett’s esophagus-related T1 esophageal adenocarcinoma. Clin Gastroenterol Hepatol 2015;13:658-664.

¹⁰ Leers JM, DeMeester SR, Oezcelik A, et al. The prevalence of lymph node metastases in patients with T1 esophageal adenocarcinoma a retrospective review of esophagectomy specimens. Ann Surg 2011;253:271-278.

¹¹ Alvarez Herrero L, Pouw RE, van Vilsteren FG, et al. Risk of lymph node metastasis associated with deeper invasion by early adenocarcinoma of the esophagus and cardia: study based on endoscopic resection specimens. Endoscopy 2010;42:1030-1036.

¹² Lee L, Ronellenfitsch U, Hofstetter WL, et al. Predicting lymph node metastases in early esophageal adenocarcinoma using a simple scoring system. J Am Coll Surg 2013;217:191-199.

¹³ Cen P, Hofstetter WL, Correa AM, et al. Lymphovascular invasion as a tool to further subclassify T1b esophageal adenocarcinoma. Cancer 2008;112:1020-1027.

¹⁴ Nentwich MF, von Loga K, Reeh M, et al. Depth of submucosal tumor infiltration and its relevance in lymphatic metastasis formation for T1b squamous cell and adenocarcinomas of the esophagus. J Gastrointest Surg 2014;18:242-249; discussion 249.

¹⁵ Newaishy GA, Read GA, Duncan W, Kerr GR. Results of radical radiotherapy of squamous cell carcinoma of the oesophagus. Clin Radiol 1982;33:347-352.

¹⁶ Okawa T, Kita M, Tanaka M, Ikeda M. Results of radiotherapy for inoperable locally advanced esophageal cancer. Int J Radiat Oncol Biol Phys 1989;17:49-54.

¹⁷ Sun DR. Ten-year follow-up of esophageal cancer treated by radical radiation therapy: analysis of 869 patients. Int J Radiat Oncol Biol Phys 1989;16:329-334.

¹⁸ Oppedijk V, van der Gaast A, van Lanschot JJ, et al. Patterns of recurrence after surgery alone versus preoperative chemoradiotherapy and surgery in CROSS trials. J Clin Oncol 2014;32:385-391.

¹⁹ Lou F, Sima CS, Adusumilli PS, et al. Esophageal cancer recurrence patterns and implications for surveillance. J Thorac Oncol 2013;8:1558-1562.

²⁰ Sudo K, Taketa T, Correa AM, et al. Locoregional failure rate after preoperative chemoradiation of esophageal adenocarcinoma and the outcomes of salvage strategies. J Clin Oncol 2013;31:4306-4310.

²¹ Dorth JA, Pura JA, Palta M, et al. Patterns of recurrence after trimodality therapy for esophageal cancer. Cancer 2014;120:2099-2105.

²² Sudo K, Xiao L, Wadhwa R, et al. Importance of surveillance and success of salvage strategies after definitive chemoradiation in patients with esophageal cancer. J Clin Oncol 2014;32:3400-3405.

²³ Taketa T, Sudo K, Correa AM, et al. Post-chemoradiation surgical pathology stage can customize the surveillance strategy in patients with esophageal adenocarcinoma. J Natl Compr Canc Netw 2014;12:1139-1144.

HEAD & NECK